Need for a unified decision-making tool for ultrafiltration therapy in heart failure; call for action

Abstract

Although ultrafiltration portends several theoretical advantages over the standard therapy for acute decompensated heart failure, it might not be the optimal treatment for all patients presenting with an episode of decompensation. It is not yet clear how to prospectively identify the subset of patients that would benefit from this therapeutic modality. Based on the pathophysiologic mechanisms underlying acute decompensated heart failure, early ultrafiltration therapy can be an appropriate initial management strategy for those patients with diuretic resistance whose associated renal dysfunction is related to hemodynamic changes rather than a structural abnormality. In the absence of widely accepted consensus guidelines, ultrafiltration use is currently subject to considerable variations among physicians. A clinical tool (eg, a scoring system) that is based on the individual patient's characteristics is therefore needed to prospectively identify the appropriate candidates for this therapy. Using this system is likely to portend better outcomes while helping to avoid unnecessary exposure to potential risks of extracorporeal therapies.